Track topics on Twitter Track topics that are important to you
To accelerate the clinical study of ACT-017, for the emergency treatment of stroke Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total amount invested to ...
The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. This Smart News Release features multimedia. Vie...
David SalazarThe product had brand and generic sales of roughly $484.4 million for the 12 months ended June 2017, according to QuintilesIMS data. read more